Concerns have been raised about the potential toxicity of propylene glycol (PG)-free melphalan treatment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant (auto-HSCT). But new data suggest those concerns may be unfounded.
Generic melphalan contains PG as one solvent. After the FDA approved PG-free melphalan (Evomela, Acrotech) in 2016, contradictory reports emerged about its toxicity, said Ko Maung, MD, of Duke Cancer